Heron Therapeutics | HRTX - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
ALKERMES USD 264.59M 77.4M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amarin USD 18.97M 1.03M 2025-12
ANI Pharmaceuticals USD 82.79M 6.13M 2025-12
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.02M 8.84M 2025-12
Eisai JPY 111.72B 7.86B 2025-12
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Esperion Therapeutics USD 39.42M 456K 2025-12
GlaxoSmithKline GBP 2.12B 558M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 212.48M 26.11M 2025-12
Ligand Pharmaceuticals USD 28.45M 8.27M 2025-09
Merck USD 2.67B 180M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Omeros USD 11.32M 2.48M 2024-09
Pacira USD 83.88M 7.99M 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Surmodics USD 11.4M 3.18M 2025-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Veracyte USD 50.84M 7.53M 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03